Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II Study of OH2 Injection, an Oncolytic Type 2 Herpes Simplex Virus Expressing Granulocyte Macrophage Colony-Stimulating Factor, in Malignant Solid Tumors

Next Previous
Search
Trial Profile

Phase I/II Study of OH2 Injection, an Oncolytic Type 2 Herpes Simplex Virus Expressing Granulocyte Macrophage Colony-Stimulating Factor, in Malignant Solid Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 26 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Irinotecan (Primary) ; OH 2 (Primary) ; Pucotenlimab (Primary)
  • Indications Gastrointestinal cancer; Head and neck cancer; Sarcoma; Soft tissue sarcoma; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Binhui Biopharmaceutical

    • Most Recent Events

    • 20 Dec 2024 Planned End Date changed from 30 Aug 2024 to 30 Aug 2025.
    • 20 Dec 2024 Planned primary completion date changed from 30 Aug 2024 to 30 Aug 2025.
    • 04 Jun 2024 Results (n=26 from a sarcoma-specific expansion cohort of the trial) assessing efficacy of oncolytic herpes simplex virus 2 and an anti-PD-1 antibody in patients with advanced sarcoma presented at the 60th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top